OnKure, Inc.   Report issue

For profit Phase 2
Founded: Longmont CO United States (2011)

Organization Overview

First Clinical Trial
2019
NCT03931681
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

OnKure, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

binimetinib (mektovi) (1 trial)

oki-179 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2